Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (1349.HK)
HKD 2.34
(1.3%)
HKD 2.34
(1.3%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 10.95 Million CNY | -29.78% |
| 2022 | 15.59 Million CNY | -30.94% |
| 2021 | 22.58 Million CNY | 66.12% |
| 2020 | 13.59 Million CNY | 540.92% |
| 2019 | 2.12 Million CNY | 0.0% |
| 2018 | - CNY | 0.0% |
| 2017 | - CNY | 0.0% |
| 2016 | - CNY | 0.0% |
| 2015 | - CNY | 0.0% |
| 2014 | - CNY | -100.0% |
| 2013 | 25 Million CNY | -37.5% |
| 2012 | 40 Million CNY | -20.0% |
| 2011 | 50 Million CNY | 200.12% |
| 2010 | 16.66 Million CNY | -62.42% |
| 2009 | 44.33 Million CNY | 43.0% |
| 2008 | 31 Million CNY | -24.39% |
| 2007 | 41 Million CNY | 105.0% |
| 2006 | 20 Million CNY | 0.0% |
| 2005 | - CNY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 9.86 Million CNY | 0.0% |
| 2024 Q2 | 8.98 Million CNY | 0.0% |
| 2023 FY | 10.95 Million CNY | -29.78% |
| 2023 Q2 | 11.18 Million CNY | -16.93% |
| 2023 Q1 | 13.46 Million CNY | -13.67% |
| 2023 Q3 | 10.42 Million CNY | -6.77% |
| 2023 Q4 | 10.95 Million CNY | 5.02% |
| 2022 Q4 | 15.59 Million CNY | -9.64% |
| 2022 FY | 15.59 Million CNY | -30.94% |
| 2022 Q3 | 17.26 Million CNY | -13.35% |
| 2022 Q2 | 19.92 Million CNY | -4.49% |
| 2022 Q1 | 20.86 Million CNY | -7.65% |
| 2021 Q3 | 24.57 Million CNY | 34.13% |
| 2021 Q2 | 18.32 Million CNY | 50.56% |
| 2021 FY | 22.58 Million CNY | 66.12% |
| 2021 Q1 | 12.16 Million CNY | -10.51% |
| 2021 Q4 | 22.58 Million CNY | -8.08% |
| 2020 Q1 | 1.24 Million CNY | -41.46% |
| 2020 Q2 | 788.05 Thousand CNY | -36.55% |
| 2020 Q3 | 11.75 Million CNY | 1391.79% |
| 2020 Q4 | 13.59 Million CNY | 15.66% |
| 2020 FY | 13.59 Million CNY | 540.92% |
| 2019 Q1 | - CNY | 0.0% |
| 2019 Q2 | 4 Million CNY | 0.0% |
| 2019 Q4 | 2.12 Million CNY | 0.0% |
| 2019 FY | 2.12 Million CNY | 0.0% |
| 2018 Q1 | - CNY | 0.0% |
| 2018 Q4 | - CNY | 0.0% |
| 2018 Q3 | - CNY | 0.0% |
| 2018 FY | - CNY | 0.0% |
| 2018 Q2 | - CNY | 0.0% |
| 2017 FY | - CNY | 0.0% |
| 2017 Q3 | - CNY | 0.0% |
| 2017 Q2 | - CNY | 0.0% |
| 2017 Q1 | - CNY | 0.0% |
| 2017 Q4 | - CNY | 0.0% |
| 2016 Q2 | - CNY | 0.0% |
| 2016 Q4 | - CNY | 0.0% |
| 2016 FY | - CNY | 0.0% |
| 2016 Q1 | - CNY | 0.0% |
| 2016 Q3 | - CNY | 0.0% |
| 2015 Q3 | - CNY | 0.0% |
| 2015 FY | - CNY | 0.0% |
| 2015 Q2 | - CNY | 0.0% |
| 2015 Q4 | - CNY | 0.0% |
| 2015 Q1 | - CNY | 0.0% |
| 2014 FY | - CNY | -100.0% |
| 2014 Q4 | - CNY | 0.0% |
| 2014 Q3 | - CNY | 0.0% |
| 2014 Q2 | - CNY | 0.0% |
| 2014 Q1 | - CNY | -100.0% |
| 2013 Q2 | 25 Million CNY | 0.0% |
| 2013 Q4 | 25 Million CNY | 0.0% |
| 2013 FY | 25 Million CNY | -37.5% |
| 2013 Q1 | - CNY | -100.0% |
| 2012 Q2 | 50 Million CNY | 0.0% |
| 2012 FY | 40 Million CNY | -20.0% |
| 2012 Q4 | 40 Million CNY | 0.0% |
| 2011 FY | 50 Million CNY | 200.12% |
| 2011 Q2 | 56.66 Million CNY | 0.0% |
| 2011 Q4 | 50 Million CNY | 0.0% |
| 2010 Q2 | 13.33 Million CNY | 0.0% |
| 2010 FY | 16.66 Million CNY | -62.42% |
| 2010 Q4 | 16.66 Million CNY | 0.0% |
| 2009 FY | 44.33 Million CNY | 43.0% |
| 2008 FY | 31 Million CNY | -24.39% |
| 2007 FY | 41 Million CNY | 105.0% |
| 2006 FY | 20 Million CNY | 0.0% |
| 2005 FY | - CNY | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 2.07 Million HKD | -428.352% |
| Grand Pharmaceutical Group Limited | 990.02 Million HKD | 98.894% |
| Extrawell Pharmaceutical Holdings Limited | 117.12 Million HKD | 90.649% |
| Wai Yuen Tong Medicine Holdings Limited | 276.2 Million HKD | 96.034% |
| Qianhai Health Holdings Limited | - HKD | -Infinity% |
| Lee's Pharmaceutical Holdings Limited | 70.63 Million HKD | 84.494% |
| Essex Bio-Technology Limited | 36.05 Million HKD | 69.624% |
| Tongfang Kontafarma Holdings Limited | 12.8 Million HKD | 14.439% |
| PuraPharm Corporation Limited | 81.09 Million HKD | 86.494% |
| SSY Group Limited | 1.94 Billion HKD | 99.438% |
| JBM (Healthcare) Limited | 43.8 Million HKD | 74.994% |
| Jacobson Pharma Corporation Limited | 592.2 Million HKD | 98.151% |
| China Resources Pharmaceutical Group Limited | 16.61 Billion HKD | 99.934% |